Medicina y salud
Disciplina temática
McGill University Health Centre
Montreal, CanadáPublicaciones en colaboración con investigadores/as de McGill University Health Centre (13)
2024
-
Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study
JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387
-
TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale
American Heart Journal, Vol. 270, pp. 86-94
2022
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
-
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic
British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96
2018
-
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma
Modern Pathology, Vol. 31, Núm. 8, pp. 1201-1210
2017
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
2015
-
Transcatheter Reduction of Paravalvular Leaks: ASystematic Review and Meta-analysis
Canadian Journal of Cardiology, Vol. 31, Núm. 3, pp. 260-269
2001
-
The Gab1 Docking Protein Links the B Cell Antigen Receptor to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and to the SHP2 Tyrosine Phosphatase
Journal of Biological Chemistry, Vol. 276, Núm. 15, pp. 12257-12265
1999
-
A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis
Journal of Biological Chemistry, Vol. 274, Núm. 44, pp. 31719-31726